This CCR Focus examines a prized target in oncology-inhibition of RAS, the GTPase signaling protein known as a molecular signaling switch and found to be mutated in many common cancers. These mutations, typically in one of three key hotspots, keep the protein always on, signaling proliferation and survival. This CCR Focus examines the intense quest under way to develop a molecule or therapeutic strategy that will inhibit RAS. The articles, guided by Guest Editor Frank McCormick, discuss various aspects of targeting RAS:
Together, these articles demonstrate a multipronged effort to block RAS, known for over 30 years to be mutated in cancer, and express cautious optimism that it is just a matter of time before we can affect RAS activity in human cancer.
After reading this CCR Focus, we no longer ask whether we "will ever have" an agent to inhibit aberrant RAS function in the clinic. Rather, we now may ask "how much benefit" we can expect to achieve. That is a complex question and, as discussed by McCormick, depends in large part on whether cancer cells remain dependent on RAS. The discovery of imatinib for chronic myelogenous leukemia (CML) created a paradigm shift in cancer research that sent the community on a search for solitary molecular targets that could fundamentally alter cancer biology. Over time, the uniqueness of the CML story has become apparent: For most other mutated oncogenic targets, long-term disease control has not been achievable, despite the availability of effective inhibitors. We expect that RAS inhibitors will shrink tumors in some cell types bearing RAS mutations, but not in all. But in 2015 we recognize that there will likely not be a "one-size-fits-all" anti-RAS drug for all RAS-driven cancers. Given all we have learned as a community, summarized in Text Box 1, this class of drugs should be one that we develop rationally with appropriate trial designs, patient selection, and confirmation of effective RAS inhibition, so that even if only a subset of patients is to derive meaningful benefit, we will be able to identify and treat that subset. And, in so doing, we will have a clear return on a 35-year investment in basic science. 
